Kymera Therapeutics filed an offering with the U.S. Securities and Exchange Commission on June 27, 2025.
2 reports, 0 independent
Updated Jun 27
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kymera Therapeutics filed an offering with the U.S. Securities and Exchange Commission on June 27, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Offering filed with US SEC with Morgan Stanley, TD Cowen, and Leerink Partners.
- The offering includes Leerink Partners and Broadridge Financial Solutions as joint book-running managers.
Keep exploring
The entities involved
-
Kymera Therapeutics
biopharmaceutical company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
TD Cowen
American investment bank
Related events
- TD Cowen and Morgan Stanley were appointed as lead book-running managers for a new offering in New York.
- SB Energy plans a U.S. IPO seeking a Nasdaq Global Select Market listing, with Morgan Stanley, Goldman Sachs, and Citigroup as joint lead book-running managers.
- Goldman Sachs and Morgan Stanley engaged in joint book-running management of a bond issuance for AstraZeneca.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- TD Cowen is managing a share offering for PMV Pharma, which has been filed with the SEC and utilizes Broadridge Financial Solutions for mailing the prospectus.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet